

1                                   **Recovery from Amblyopia in Adulthood: A Meta-Analysis**

2

3   **Running title: Recovery from Amblyopia in Adulthood**

4

5   **Authors:**     Madison P. Echavarri-Leet<sup>1</sup>; Hannah H. Resnick, MD, MPhil<sup>2,3</sup>; Daniel A.  
6                   Bowen<sup>1,4</sup>; Deborah Goss<sup>5</sup>; Mark F. Bear, PhD<sup>1</sup>; Eric D. Gaier, MD, PhD<sup>1,3,4</sup>

7

8   **Affiliations:** <sup>1</sup> Picower Institute for Learning and Memory, Massachusetts Institute of  
9                   Technology, Cambridge, MA

10                   <sup>2</sup> Department of Pediatrics, Massachusetts General Hospital, Boston, MA

11                   <sup>3</sup> Harvard Medical School, Boston, MA

12                   <sup>4</sup> Department of Ophthalmology, Boston Children’s Hospital, Boston, MA

13                   <sup>5</sup> Howe Library, Massachusetts Eye and Ear, Boston, MA

14

15   **Correspondence:** Eric D. Gaier, MD PhD  
16                   Department of Ophthalmology  
17                   Boston Children’s Hospital  
18                   300 Longwood Ave  
19                   Boston, MA 02115  
20                   Phone: 617-355-6401  
21                   Email: [eric.gaier@childrens.harvard.edu](mailto:eric.gaier@childrens.harvard.edu)

22

23   **Funding:**     MPL: NIH F31 EY033996  
24                   MFB: NIH R01 EY029245, RPB #42894, Picower Neurological Disorder  
25                   Research Fund  
26                   EDG: NIH K08 EY030164, Children’s Hospital Ophthalmology Foundation

27

28   **Conflict of interest statement:**  
29                   MFB: Luminopia, Inc. (scientific advisor, equity)  
30                   EDG: Luminopia, Inc. (scientific advisor, equity, patent), Stoke  
31                   Therapeutics Inc. (consultant)

32

33   **Key words:** Amblyopia, vision loss, retinal ganglion cells, neuroplasticity

34

35

36 **Abstract**

37 *Purpose:*

38 The effectiveness of traditional amblyopia therapies is largely restricted to childhood.  
39 However, recovery in adulthood is possible following removal or vision-limiting disease  
40 of the fellow eye. Study of this phenomenon is currently limited to isolated case reports  
41 and a few case series, with reported incidence ranging from 19-77%<sup>1-5</sup>. We set out to  
42 accomplish two distinct goals: (1) define the incidence of clinically meaningful recovery  
43 and (2) elucidate the clinical features associated with greater amblyopic eye gains.

44 *Methods:*

45 A systematic review of 3 literature databases yielded 23 reports containing 109 cases of  
46 patients  $\geq 18$  years old with unilateral amblyopia and vision-limiting fellow eye pathology.

47 *Results:*

48 Study 1 revealed 25/42 (59.5%) of adult patients gained  $\geq 2$  logMAR lines in the  
49 amblyopia eye after FE vision loss. The overall degree of improvement is clinically  
50 meaningful (median 2.6 logMAR lines). Study 2 showed that for cases with amblyopic  
51 eye visual acuity improvement, recovery occurs within 12 months of initial loss of fellow  
52 eye vision. Regression analysis revealed that younger age, worse baseline acuity in the  
53 amblyopic eye, and worse vision in the fellow eye independently conferred greater gains  
54 in amblyopic eye visual acuity. Recovery occurs across amblyopia types and fellow eye  
55 pathologies, although disease entities affecting fellow eye retinal ganglion cells  
56 demonstrate shorter latencies to recovery.

57 *Conclusions:*

58 Amblyopia recovery after fellow eye injury demonstrates that the adult brain harbors the  
59 neuroplastic capacity for clinically meaningful recovery, which could potentially be  
60 harnessed by novel approaches to treat adults with amblyopia.

61

## 62 **Introduction**

63 Amblyopia is a prevalent visual disorder resulting from abnormal visual  
64 experience during early development<sup>6-8</sup>. The long-standing and current treatment  
65 standard involves occlusion via patching or pharmacologic cycloplegia of the fellow eye  
66 (FE). While most children with amblyopia experience visual acuity (VA) gains in the  
67 amblyopic eye (AE) following standard therapy, improvement is often incomplete and  
68 restricted to cases where therapy is initiated before age 8<sup>9, 10</sup>. As such, treatment of  
69 amblyopia is widely considered futile in adults in routine ophthalmic practice.

70 There is extensive evidence that at least partial recovery from amblyopia can  
71 occur in experimental animal models late in the critical period (when simple occlusion-  
72 type interventions fail) and beyond<sup>11-14</sup>. For instance, experiments in mice and cats  
73 show that temporary inactivation of retinal ganglion cell (RGC) activity in both eyes or  
74 just the FE establishes conditions that enable the rapid and durable recovery from  
75 amblyopia<sup>15-17</sup>. This intervention is effective at ages when reversed occlusion  
76 (analogous to patch therapy in humans) fails to promote sustained recovery<sup>16, 17</sup>.  
77 Enucleation and retinal lesioning similarly promote recovery in visual cortical responses  
78 to stimulation of AEs of adult cats, monkeys, and mice<sup>18-22</sup>. Direct limitation of RGC  
79 activity is a common theme distinguishing the interventions that successfully drive  
80 recovery in older animals from those that do not. Thus, the pre-clinical, experimental

81 basis for amblyopia recovery in adulthood is strong and broad, but comprehensive  
82 supporting evidence in humans is needed.

83 Analogous observations of recovery from amblyopia triggered in human patients  
84 who suffer vision-limiting FE disease or loss spans decades of clinical literature. To  
85 date, there have been 5 dedicated studies examining amblyopia recovery following FE  
86 vision loss; 3 focus on specific FE disorders (ischemic optic neuropathy<sup>1</sup>, age-related  
87 macular degeneration<sup>2</sup>, uveal melanoma<sup>3</sup>), and 2 include all causes of FE visual loss<sup>4, 5</sup>.  
88 Additionally, numerous isolated reports describe the clinical courses of 1-3 patients in  
89 various clinicopathologic contexts. Despite this substantial literature, key features of this  
90 important phenomenon, which may hold the key to reversal of amblyopia in adulthood,  
91 remain undefined.

92 To begin to fill this knowledge gap, we integrated and analyzed all available  
93 clinical descriptions of AE VA recovery in the context of FE disease in adults. We aimed  
94 to (1) describe the prevalence and magnitude of recovery and (2) answer whether  
95 specific clinical metrics influence the magnitude of AE VA gains. We tested the  
96 hypotheses that direct FE RGC injury and absence of strabismus would confer greater  
97 AE VA improvement.

98

## 99 **Methods**

### 100 *Database Search*

101 A systematic search of PubMed (1946-), Embase (1947-), and Web of Sciences  
102 Core Collection (1900-) databases was conducted using combinations of the following  
103 key words: “amblyopia”, “recov-”, “revers-”, “loss”, “injury”, “visual impairment”, “fellow”,

104 “fixating”, “dominant”, “good”, “contralateral”, “eye”. Initial searches were designed and  
105 executed by HHR and DG. Final searches were run on December 21<sup>st</sup>, 2021. A total of  
106 1660 unique abstracts (deduplication from 2925 using Endnote X7.8) were returned.  
107 Covidence software (<https://www.covidence.org>) was used to manage the review  
108 process. Each unique abstract was screened by two independent team members, and  
109 conflicts were resolved by EDG. PRISMA guidelines were used for documentation<sup>23</sup>.

110

### 111 *Article inclusion*

112 Abstracts were screened based on the following inclusion criteria: cases of  
113 human adults ( $\geq 18$  years of age) with amblyopia and FE vision loss; provides individual  
114 patient-level data; provides at least 2 AE VA measurements at different timepoints.

115

### 116 *Article exclusion*

117 Articles focused on basic neuroscience/experimental techniques/interventions  
118 were excluded. Reports that were not published, were not primary articles (e.g., book  
119 chapters, lectures, abstracts, presentations, reviews) or were not available in English  
120 were excluded.

121

### 122 *Literature analysis:*

123 After abstract screening, 35 articles were reviewed in detail, and 17 ultimately  
124 met all inclusion and exclusion criteria. Bibliographies of each included report were  
125 reviewed for additional potentially relevant reports not captured in our database  
126 searches. All referenced studies were collected and reviewed in detail, yielding 6

127 additional reports meeting criteria. In total, 23 reports (comprised of 109 unique cases)  
128 were included for analysis (Supplemental Figure 1).

129

130 *Data Extraction:*

131 Each report was comprehensively and systematically examined. We extracted all  
132 parameters of interest for further analysis for each patient when available, including:

- 133 - Initial AE VA before the injury, if available, or else at the time of first evaluation  
134 after FE vision loss.
- 135 - Best measured AE VA after FE vision loss.
- 136 - Time interval from FE visual loss to best AE VA measurement (in months). If the  
137 time fell in the middle of the month or the exact length of time could not be  
138 determined, the time was rounded to the next month. If months were not  
139 provided for each timepoint, the difference in years was multiplied by 12. Times  
140 less than 1 month were rounded to one month.
- 141 - FE VA nadir, defined as the worst reported FE VA after onset of FE visual loss
- 142 - Patient age at the time of FE loss; age was binned as 18-40, 41-60, and  $\geq 61$   
143 years for analysis.

144 All VA measures were converted to the logarithm of the minimum angle of resolution  
145 (logMAR) scale and rounded to the nearest 0.02 unit (1 letter). AE VA logMAR lines of  
146 improvement was calculated from best-initial AE VA logMAR values.

147

148 *Analysis:*

149           We conducted 2 separate goal-directed studies. Study 1 aimed to determine the  
150 incidence and magnitude of AE VA improvement. To minimize the influence of reporting  
151 bias, only series reporting consecutive subjects with patient-level data within a defined  
152 study period (agnostic to whether recovery occurred for each individual patient) were  
153 included (42 cases, 3 series). Study 2 aimed to describe the clinical features associated  
154 with AE VA gains and thus focused on only cases with measurable ( $>0.0$  logMAR)  
155 improvement (101 cases, 23 reports). Among these, 55 cases specified FE VA  
156 measurements (to assess the influence of FE visual loss magnitude), 37 cases  
157 specifically reported on the presence/absence of strabismus (for segregation by  
158 amblyopia type), 38 cases had a clearly documented cause of FE vision loss (for  
159 segregation by direct RGC involvement), and 80 cases specified the timeline from FE  
160 vision loss to key AE VA measurement in follow-up (to assess temporal rate of  
161 recovery) (Figure 1).

162

163 *Statistics:*

164           Normality of data was assessed with the Kolmogorov-Smirnov test. Direct  
165 comparisons between two normally distributed groups employed a two-tailed t-test,  
166 whereas those involving one or more groups that were not normally distributed  
167 employed a Mann-Whitney test. In the case of comparing initial to best AE VA values  
168 (which were not normally distributed) a Wilcoxon matched-pairs test was used to assess  
169 whether changes in individual case AE VA values changed significantly. A univariate  
170 multiple regression was performed (SPSS, IBM, Armonk, NY) with input variables: age,  
171 baseline AE VA, FE VA nadir. The output variable was AE VA (logMAR lines) of

172 improvement. A modified Breusch-Pagan test determined that the data were  
173 heteroskedastic ( $p=0.006$ ). To control for this, robust standard errors calculation (HC3)  
174 was used in calculations of  $p$ -values in the linear regression. Bias in the linear model  
175 based on whether data came from a paper with a small sample size ( $\leq 3$  cases) or a  
176 larger sample size ( $> 3$  cases) was assessed by comparing the effect size of each of the  
177 independent variables<sup>24 25</sup>. The threshold for statistical significance was set at  $p < 0.05$  in  
178 all cases.

179

## 180 **Results:**

### 181 *STUDY 1: Incidence of clinically meaningful recovery*

182 Of the 109 reports revealed by our review, 23 were isolated case reports or small  
183 ( $\leq 3$  cases) series. To mitigate the effects of reporting bias through underrepresentation  
184 of cases without recovery, we analyzed the 42 cases originating from 3 reports  
185 containing  $> 3$  cases that were agnostic to the occurrence of recovery and included  
186 patient-level data.

187 Among these 42 cases, the median change in AE VA was 2.60 logMAR lines  
188 [IQR:0.95-4.00] . Eight (19.0%) had no AE VA improvement. Among the remaining  
189 cases, 34 (81.0%) had measurable AE VA improvement, 32 (76.2%) gained  $\geq 1$  logMAR  
190 line, 25 (59.5%) gained  $\geq 2$  logMAR lines, and 21 (50.0%) cases gained  $\geq 3$  lines (Figure  
191 2). These findings demonstrate a high incidence of clinically meaningful recovery  
192 among adults after loss of vision in the FE.

193

### 194 *STUDY 2: Features influencing amblyopic eye recovery*



195 To identify clinical factors associated with greater AE VA improvement after FE  
196 vision loss, we narrowed the 109 cases in our review to the 101 who demonstrated AE  
197 VA gains. Among these, median initial AE VA was 1.00 logMAR [IQR: 0.50-1.00]. The  
198 median best AE VA following FE vision loss was 0.22 logMAR [IQR: 0.10-0.42] (Figure  
199 3A, B). The median change in AE VA following loss of vision in the FE was 5.0 logMAR  
200 lines of improvement, which was significant via a Wilcoxon matched-pairs test  
201 ( $p < 0.0001$ ). 84/101 (83.2%) of patients exhibited  $\geq 3.0$  logMAR lines of improvement  
202 (Figure 3C). Median time from FE vision loss to maximum AE VA was 12.0 months  
203 [IQR: 6.25-24.00] (Figure 3D), though this likely reflects a frequent timepoint for  
204 scheduled follow up.

205

#### 206 *Linear modeling of clinical feature influence on recovery*

207 A linear model was constructed to assess the relationship between binned age,  
208 initial AE VA, and FE VA nadir with logMAR lines of improvement for the AE following  
209 FE vision loss. This analysis was restricted to the 55 available cases with recorded FE  
210 VA data. Younger age was associated with greater AE VA gains with an effect size of  
211 1.7 logMAR lines for each younger age bin ( $p = 0.002$ ). More severe amblyopia was  
212 associated with greater AE VA gains with an effect size of 4.9 logMAR lines of  
213 improvement ( $p < 0.001$ ). Worse FE VA nadir correlated with greater AE VA gains, with  
214 an effect size of 1.0 logMAR lines of improvement ( $p = 0.005$ ) (Figure 4).

215

#### 216 *Hypothesis-driven categorical clinical feature influence on recovery*

217           Amblyopia etiology was unavailable for 64 patients, so they were not included in  
218 this analysis. 18 patients had a history or presence of strabismus, and 19 patients did  
219 not. There was no significant difference in AE VA improvement between those with  
220 (median: 4.00 [IQR: 1.95-8.40]) versus those without (median: 3.90 [IQR: 2.20-6.00])  
221 strabismus ( $p>0.9$ ; Mann-Whitney test). (Figure 5A).

222           Of the 101 cases found through our systematic literature search, 38 had clear  
223 documentation relating to the cause of FE vision loss where direct involvement of RGCs  
224 could be ascertained. Of those 38 cases, 22 cases of FE vision loss with RGC  
225 involvement and 16 cases without RGC involvement. There was no significant  
226 difference in AE VA improvement between cases with (median: 3.00 [IQR: 1.80- 8.20])  
227 and without (median: 4.00 [IQR: 3.00-8.20]) RGC injury ( $p>0.3$ , Mann-Whitney test).  
228 Comparing rate of recovery, those with RGC injury saw faster improvement in AE VA  
229 (median: 8 months [IQR: 2-19]) than those without (median: 12 months [IQR: 12-41];  
230  $p=0.0124$ , Mann-Whitney test) (Figure 5B, C)

231

232 *Post-hoc assessment of study bias:*

233           Our systematic review returned reports that contained larger case series with  $>3$   
234 cases ( $n=5$ ) and case reports/smaller case series ( $\leq 3$  cases) ( $n=18$ ). Because larger  
235 case series contributed 78/101 (77.2%) cases, we asked whether this distribution could  
236 influence the results. There was no significant difference between AE VA gains between  
237 those contributed by larger case series (median: 4.80 [IQR: 3.00-7.00]) and small case  
238 series/reports (median: 7.00 [IQR: 3.90-8.60];  $p=0.098$ , Mann-Whitney test)  
239 (Supplemental Figure 2A). Confidence intervals for each case series and the composite

240 of small series and isolated reports overlap the median of 5.0 logMAR lines of AE VA  
241 improvement for the overall sample without systematic bias trends (Supplemental  
242 Figure 2B). We assessed whether the linear clinical factors found to influence AE VA  
243 improvement differed systematically across studies. There were no significant  
244 differences in regression weights between groups (*binned age*  $Z=0.056$ ,  $p>0.9$ ; *initial*  
245 *AE VA*  $Z=1.465$ ,  $p>0.14$ ; *FE VA nadir*  $Z=0.704$ ,  $p>0.4$ ), suggesting neither report type  
246 imparts measurable bias on regression weights for linear clinical factors. Thus, there  
247 was no clear evidence of bias imparted by report type or size on the primary outcome  
248 measure in Study 2.

249

## 250 **Discussion**

251 Although conventional occlusion therapy is not effective in adults with amblyopia,  
252 gains in AE VA following FE vision loss is common. Integration and analysis of reported  
253 cases demonstrate that the adult visual system retains the capacity for plasticity  
254 necessary for recovery from amblyopia. These results show that 60% of adults with  
255 amblyopia who experience FE vision loss will gain at least 2 lines of AE VA. Amblyopia  
256 treatment trials in children <8 years of age reporting an average of 2-3 logMAR lines of  
257 improvement following 3-6 months of occlusion treatment suggest that the prevalence of  
258 recovery is substantial<sup>8</sup>. By comparison, only 25% of 13–17-year-olds (and 47% of  
259 treatment naïve 13–17-year-olds) gain  $\geq 2$  lines of AE VA following 2-6 hours of daily  
260 patching<sup>26</sup>. While randomized control trials in adults are not available, this comparison  
261 suggests that the rate of AE VA improvement seen after FE vision loss markedly  
262 exceeds conventional occlusion therapy.

263 We focused our study of clinical factors on cases with some degree of AE VA  
264 improvement to avoid over-representation of recovered cases by inclusion of isolated  
265 reports. In this sample, we found that improvement is generally observed within 12  
266 months following FE vision loss, and further gains after this time point are less common.  
267 Most amblyopia is associated with anisometropia, strabismus, or both<sup>27</sup>. A history of or  
268 presence of strabismus did not influence the degree of AE VA recovery in our study  
269 despite more blunted gains<sup>28</sup> and higher rates of regression<sup>29</sup> in conventionally treated  
270 strabismic compared to anisometropic amblyopia. Given that previous research  
271 indicates that temporary inactivation of FE RGCs promotes recovery from amblyopic  
272 rearing in mice and cats, we postulated that direct RGC involvement may be required to  
273 enable the plasticity necessary to drive recovery in older age, but our results suggest  
274 this is not necessarily the case<sup>15, 16</sup>. We noted comparable rates of recovery in outer  
275 retinal disorders such as age-related macular degeneration<sup>2</sup> and uveal melanoma<sup>3</sup> as  
276 with ischemic optic neuropathy<sup>1</sup>. FE injury directly involving RGC damage did not affect  
277 the magnitude of AE VA gains but did confer a faster rate of recovery. Though the  
278 current analyses focus on injuries involving damage to RGCs, future work could  
279 potentially compare pre-retinal (e.g. corneal, lenticular) and retinal/optic nerve disorders.

280 It is well-documented that the success of amblyopia treatment depends on  
281 patient age, and that adults generally do not respond to conventional amblyopia  
282 treatment methods<sup>8, 10, 11, 30, 31</sup>. Although our analysis was restricted to adult patients, we  
283 were curious whether patient age at the time of FE loss would be a factor associated  
284 with degree of AE VA improvements. Linear regression analysis showed that younger  
285 age, greater severity of vision loss in the FE, and worse initial AE VA independently

286 influenced the degree of improvement in the AE VA. These results may be applied in  
287 clinical contexts to prognosticate the degree of AE recovery in new cases of FE vision  
288 loss.

289 Our study has several limitations, mainly stemming from factors inherent to the  
290 nature of meta-analyses. The availability and reliability of data could not be controlled in  
291 this systematic literature review spanning many decades, journals and report types.  
292 Subgroup analyses and linear models engaged fractions of our sample because of  
293 inconsistencies in reported details between cases and reports, and thus there is some  
294 susceptibility to bias within our sample. This underscores the importance of our post-  
295 hoc analysis, which demonstrated no systematic biases of report type on either the  
296 primary outcome measure or the factors found to be influential through linear modeling.  
297 Despite these inherent limitations, the relative infrequency of this clinical problem (owing  
298 to a need for two separate ophthalmic conditions in each eye: amblyopia and vision-  
299 limiting FE pathology) necessitates meta-analysis as the only feasible means to test our  
300 hypotheses. However, advancement of means to build and integrate large medical  
301 databases could provide another means to study this phenomenon in the future,  
302 provided that the minimal patient-level details such as laterality are available.

303 The Bienenstock, Cooper, and Munro (BCM) theory of metaplasticity<sup>32</sup> provides a  
304 useful conceptual framework to understand how FE vision loss can drive AE recovery<sup>14</sup>.  
305 The BCM theory posits that the threshold for cortical synaptic potentiation changes as a  
306 function of the history of integrated post-synaptic neuronal activity. In this clinical  
307 context, the reduction in visual cortical activity following FE vision loss lowers the  
308 plasticity threshold to enable potentiation of synapses serving the AE, ultimately

309 improving AE visual function. Of course, permanent FE vision loss is not a viable  
310 treatment approach. However, according to this theoretical model, even temporary  
311 silencing of the FE may be sufficient to enable synapses serving the AE to grow in  
312 strength and, importantly, maintain these improvements even when the FE activity  
313 returns to normal. Understanding the molecular, cellular and circuitry contributions to  
314 metaplasticity<sup>14, 33-35</sup> may lead to novel amblyopia therapies in adults. Experimental  
315 elucidation of the relevant mechanisms through animal models will serve to refine  
316 potential therapeutic targets whereby the plasticity that enables recovery from  
317 amblyopia in adulthood could one day be harnessed.

318

#### 319 **Acknowledgements:**

320 Hui Li, PhD candidate in biostatistics at the Harvard T.H. Chan of Public Health, for  
321 statistical consultation.

322

#### 323 **Figure Legends:**

324 **Figure 1: Inclusion criteria and case selection for Studies 1 and 2.** 109 cases from  
325 23 papers met our initial inclusion criteria. To determine the incidence of AE VA  
326 improvement following FE VA loss for Study 1, we only included papers that reported  
327 both positive and negative results to minimize the influence of reporting bias. Only 3 of  
328 the 23 papers reported negative and positive results; the remaining 20 papers only  
329 reported positive cases. Thus, only the 42 cases from these 3 papers were included in  
330 Study 1. In Study 2, we focused only on cases where some degree of AE VA  
331 improvement was observed. 101 cases from 23 papers met this criterion. Some

332 analyses within Study 2 were restricted to cases in which specific data were available:  
333 time course to maximal AE (n=80), FE VA nadir (n=55), strabismus status (n=37), and  
334 etiology of FE vision loss (n=38).

335

336 **Figure 2: Following fellow eye vision loss, the majority of adults improve visual**  
337 **acuity in the amblyopic eye. (A)** Three dedicated studies met our inclusion criteria for  
338 the purposes of Study 1, with a similar incidence of recovery observed in each.

339 **(B)** Pie chart illustrating how many cases had various degrees of AE VA improvement.

340

341 **Figure 3: For most adult amblyopes who improve amblyopic eye visual acuity**  
342 **following loss of vision in the fellow eye, recovery occurs within 12 months. (A)**  
343 Box plots depicting median logMAR VA (black line) at baseline (blue) and maximal AE  
344 VA following FE vision loss (red) (\*\*\*\*  $p < 0.0001$ ). The top and bottom borders of the box  
345 indicate quartiles, and whiskers indicate minimum and maximum values (n=101). **(B)**  
346 Individual case data of baseline and maximal AE VA (n=101). **(C)** Violin plot depicting  
347 the distribution of AE VA improvement for all cases (n=101). The red line depicts the  
348 median, and blue lines depict quartiles. **(D)** Violin plot depicting the distribution of time  
349 from FE vision loss to maximal AE VA (n=80). The red line depicts the median, and blue  
350 lines depict quartiles.

351

352 **Figure 4: Linear modeling reveals younger age, worse initial amblyopic eye visual**  
353 **acuity, and worse fellow eye visual acuity following vision loss are independently**  
354 **associated with greater amblyopic eye visual acuity improvement. (A)** Effect sizes

355 of significant factors identified by multiple linear regression using robust standard errors.  
356 Bars represent 95% confidence intervals. **(B)** Mesh grids of predicted values and  
357 calculated slope from the linear model segregated by age bins: 18-40 (left), 41-60  
358 (center), 61+ (right). Individual case AE VA improvement values are represented by  
359 black dots and lines connect to the plane of best fit.

360

361 **Figure 5: Testing the influence of categorical clinical features of amblyopia or**  
362 **fellow eye vision loss on the degree of amblyopia eye visual acuity recovery. (A)**  
363 Box plots depicting median logMAR line VA improvement (black line) according to  
364 strabismus status (ns  $p>0.9$ ; Mann-Whitney test). Top and bottom borders of the boxes  
365 indicate quartiles and whiskers indicate range. **(B)** Box plots depicting median logMAR  
366 line VA improvement (black line) according to FE pathology involvement of retinal  
367 ganglion cells (RGCs) (ns  $p>0.3$ ; Mann-Whitney test). **(C)** Box plots depicting median  
368 time to maximal AE VA (black line) according to FE pathology involvement of RGC (\*  
369  $p=0.0124$ ; Man-Whitney test).

370

371 **Supplemental Figure 1: Method for collection and inclusion of relevant reports**  
372 **and cases.**

373 A systematic search of PubMed (1946-), Embase (1947-), and Web of Sciences Core  
374 Collection (1900-) databases was conducted and returned 2925 papers. After  
375 deduplication, 1660 abstracts were screened by two members of the team for  
376 relevance. 35 papers were sought for retrieval and the relevance was assessed based  
377 on the article in its entirety. We ultimately determined that 17 of these papers met our



378 eligibility criteria for inclusion in the meta-analysis. Eligible papers then had their  
379 individual bibliographies reviewed. Non-duplicate references were retrieved, and 39  
380 additional sources were screened for relevance. 10 ultimately were reviewed in full, and  
381 6 of these met eligibility criteria and were included in the final meta-analysis. In total 23  
382 reports comprised of 109 cases were included. PRISMA guidelines were used for this  
383 documentation <sup>23</sup>.

384

### 385 **Supplemental Figure 2: Assessing potential bias in primary outcome measure**

386 **(logMAR lines of recovery) by report type. (A)** AE VA (logMAR lines) improvement  
387 segregated by report type (ns  $p=0.098$ ; Mann-Whitney test). Error bars indicate 95%  
388 confidence interval. Black dotted line indicates the median ( $y = 5.0$  logMAR lines of AE  
389 VA improvement) for all cases, regardless of report type. **(B)** Forest plot comparing the  
390 median logMAR lines of AE VA improvement (black dots) with 95% confidence intervals  
391 (error bars) for all case series containing  $>3$  cases individually and pooled case reports  
392 and case series containing  $\leq 3$  cases. The number of reported cases and authors for  
393 each report of case series comprise the y-axis labels. Red dotted line ( $x = 5.0$ ) indicates  
394 the median logMAR lines of AE VA improvement for all cases, regardless of report type.

395

### 396 **Supplemental Table 1: Summary of individual case details**

397 A table of all included cases and factors analyzed. Author/Paper: yellow indicates this  
398 case was included in Study 1, and grey indicates it was not. Lines of improvement:  
399 green indicates this case was included in Study 2, and red indicates it was not. Time to  
400 best (months) and Worst FE VA (logMAR): orange indicates this information was

401 available and included in the analysis, and grey indicates it was not. Binned age: pink  
402 indicates patients aged 18-40 (group 1), yellow indicates patients aged 41-60 (group 2),  
403 and green indicates patients aged 61+ (group 3). History of strabismus: orange  
404 indicates patients with a history or presence of strabismus, purple indicates patients  
405 without a history or presence of strabismus, and grey indicates patients that were not  
406 included in this analysis (either because this information was not available or because  
407 the patient did not show AE VA improvement). RGC Damage: red indicates patients  
408 with RGC damage, blue indicates patients without RGC damage, and grey indicates  
409 patients excluded from this analysis because the RGC status was unclear.

410


#### 411 **References:**

- 412 1. Resnick HH, Bear MF, Gaier ED. Partial Recovery of Amblyopia After Fellow Eye  
413 Ischemic Optic Neuropathy. *J Neuroophthalmol* 2023;43:76-81.
- 414 2. El Mallah MK, Chakravarthy U, Hart PM. Amblyopia: is visual loss permanent?  
415 *The British journal of ophthalmology* 2000;84:952-956.
- 416 3. Vagge A, Shields CL, Shields JA, Pointdujour-Lim R, Schnall B. Visual  
417 improvement in amblyopic eye following treatment-induced vision loss in dominant eye  
418 with uveal melanoma. *The British journal of ophthalmology* 2020;104:202-207.
- 419 4. Rahi JS, Logan S, Borja MC, Timms C, Russell-Eggitt I, Taylor D. Prediction of  
420 improved vision in the amblyopic eye after visual loss in the non-amblyopic eye. *Lancet*  
421 2002;360:621-622.
- 422 5. Vereecken EP, Brabant P. Prognosis for vision in amblyopia after the loss of the  
423 good eye. *Arch Ophthalmol* 1984;102:220-224.
- 424 6. Fu Z, Hong H, Su Z, Lou B, Pan CW, Liu H. Global prevalence of amblyopia and  
425 disease burden projections through 2040: a systematic review and meta-analysis. *The*  
426 *British journal of ophthalmology* 2020;104:1164-1170.
- 427 7. Maurer D, Mc KS. Classification and diversity of amblyopia. *Vis Neurosci*  
428 2018;35:E012.
- 429 8. Birch EE. Amblyopia and binocular vision. *Progress in retinal and eye research*  
430 2013;33:67-84.
- 431 9. Holmes JM, Lazar EL, Melia BM, et al. Effect of age on response to amblyopia  
432 treatment in children. *Arch Ophthalmol* 2011;129:1451-1457.
- 433 10. Holmes JM, Levi DM. Treatment of amblyopia as a function of age. *Vis Neurosci*  
434 2018;35:E015.

- 435 11. Hensch TK. Critical period plasticity in local cortical circuits. *Nature reviews*  
436 *Neuroscience* 2005;6:877-888.
- 437 12. Hensch TK, Quinlan EM. Critical periods in amblyopia. *Vis Neurosci*  
438 2018;35:E014.
- 439 13. Spolidoro M, Sale A, Berardi N, Maffei L. Plasticity in the adult brain: lessons  
440 from the visual system. *Exp Brain Res* 2009;192:335-341.
- 441 14. Leet MP, Bear MF, Gaier ED. Metaplasticity: a key to visual recovery from  
442 amblyopia in adulthood? *Curr Opin Ophthalmol* 2022;33:512-518.
- 443 15. Fong MF, Mitchell DE, Duffy KR, Bear MF. Rapid recovery from the effects of  
444 early monocular deprivation is enabled by temporary inactivation of the retinas.  
445 *Proceedings of the National Academy of Sciences of the United States of America*  
446 2016;113:14139-14144.
- 447 16. Fong MF, Duffy KR, Leet MP, Candler CT, Bear MF. Correction of amblyopia in  
448 cats and mice after the critical period. *Elife* 2021;10.
- 449 17. Duffy KR, Fong MF, Mitchell DE, Bear MF. Recovery from the anatomical effects  
450 of long-term monocular deprivation in cat lateral geniculate nucleus. *J Comp Neurol*  
451 2018;526:310-323.
- 452 18. Harwerth RS, Smith EL, 3rd, Crawford ML, von Noorden GK. Effects of  
453 enucleation of the nondeprived eye on stimulus deprivation amblyopia in monkeys.  
454 *Invest Ophthalmol Vis Sci* 1984;25:10-18.
- 455 19. Hendrickson A, Boles J, McLean EB. Visual acuity and behavior of monocularly  
456 deprived monkeys after retinal lesions. *Invest Ophthalmol Vis Sci* 1977;16:469-473.
- 457 20. Kratz KE, Spear PD, Smith DC. Postcritical-period reversal of effects of  
458 monocular deprivation on striate cortex cells in the cat. *Journal of neurophysiology*  
459 1976;39:501-511.
- 460 21. Hoffmann KP, Lippert P. Recovery of vision with the deprived eye after the loss  
461 of the non-deprived eye in cats. *Hum Neurobiol* 1982;1:45-48.
- 462 22. Drager UC. Observations on monocular deprivation in mice. *Journal of*  
463 *neurophysiology* 1978;41:28-42.
- 464 23. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an  
465 updated guideline for reporting systematic reviews. *BMJ (Clinical research ed)*  
466 2021;372:n71.
- 467 24. Clogg CC, Petkova E, Haritou A. Statistical methods for comparing regression  
468 coefficients between models. *American journal of sociology* 1995;100:1261-1293.
- 469 25. Brame R, Paternoster R, Mazerolle P, Piquero A. Testing for the equality of  
470 maximum-likelihood regression coefficients between two independent equations.  
471 *Journal of quantitative criminology* 1998;14:245-261.
- 472 26. Scheiman MM, Hertle RW, Beck RW, et al. Randomized trial of treatment of  
473 amblyopia in children aged 7 to 17 years. *Arch Ophthalmol* 2005;123:437-447.
- 474 27. Levi DM, McKee SP, Movshon JA. Visual deficits in anisometropia. *Vision Res*  
475 2011;51:48-57.
- 476 28. Woodruff G, Hiscox F, Thompson JR, Smith LK. Factors affecting the outcome of  
477 children treated for amblyopia. *Eye (Lond)* 1994;8 ( Pt 6):627-631.
- 478 29. Levartovsky S, Oliver M, Gottesman N, Shimshoni M. Factors affecting long term  
479 results of successfully treated amblyopia: initial visual acuity and type of amblyopia. *The*  
480 *British journal of ophthalmology* 1995;79:225-228.


- 481 30. Bear MF. Bidirectional synaptic plasticity: from theory to reality. *Philos Trans R*  
482 *Soc Lond B Biol Sci* 2003;358:649-655.
- 483 31. Wu C, Hunter DG. Amblyopia: diagnostic and therapeutic options. *Am J*  
484 *Ophthalmol* 2006;141:175-184.
- 485 32. Bienenstock EL, Cooper LN, Munro PW. Theory for the development of neuron  
486 selectivity: orientation specificity and binocular interaction in visual cortex. *J Neurosci*  
487 1982;2:32-48.
- 488 33. Philpot BD, Espinosa JS, Bear MF. Evidence for altered NMDA receptor function  
489 as a basis for metaplasticity in visual cortex. *J Neurosci* 2003;23:5583-5588.
- 490 34. Cho KK, Khibnik L, Philpot BD, Bear MF. The ratio of NR2A/B NMDA receptor  
491 subunits determines the qualities of ocular dominance plasticity in visual cortex.  
492 *Proceedings of the National Academy of Sciences of the United States of America*  
493 2009;106:5377-5382.
- 494 35. Linden ML, Heynen AJ, Haslinger RH, Bear MF. Thalamic activity that drives  
495 visual cortical plasticity. *Nature neuroscience* 2009;12:390-392.
- 496

**Figure 1**




# Figure 2

## A




## B




Total=42

**Figure 3**


**A**




**B**





**C**




**D**




**Figure 4****A****B**



41-60 years



61+ years





**Figure 5****A****B****C**